Advanced Tumor Models for Oncology and Immunotherapy Research

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

• A large collection of cell line-derived xenograft (CDX) tumor models covering 30 tumor types
• Imaging based orthotopic/metastatic CDX platform, covering 15 tumor types
• Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
• Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
• Human immune checkpoint gene KI mouse models
• hPBMC/HSC humanized models
• Extensive panel of c-MET related CDX and PDX tumor models
• In Vivo Models of Tumor Complications

Cell Line-derived Xenograft (CDX) Tumor Models

• Available data of sensitivities to SOC (standard of care)
• Imaging-based orthotopic/metastatic tumor models
• Brain/bone metastatic models of lung/breast cancer cell lines

* indicates model validated with SOC compound

445 Subcutaneous Xenograft Models Covering 31 Tumor Types

82 Experimental Metastasis Xenograft Models Covering 11 Tumor Types

48 Experimental Metastasis Xenograft Models Covering 14 Tumor Types

Patient-derived Xenograft (PDX) Tumor Models

• 1,400+ PDX models covering full range of cancer types
• Fully-characterized models with genetic, molecular and pharmacological profiling
• Drug-resistant models, including a clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
• in vitro screening and derivative PDXC/PDXO models
• IO-PDX panel with hPBMC humanization

Syngeneic tumor models

• 87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
• Comprehensive panel of orthotopic syngeneic tumor models
• Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
• Tumor-infiltrating leukocytes (TILs) map
• WES, RNA-seq and scRNA-seq characterization

Genetically engineered models

• 48 engineered cell lines based on construct overexpression or gene knock-in
• Pharmacologically validated both in vitro and in vivo
• Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
• Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

hPBMC/HSC Humanized Models

hPBMC Humanized Models

• Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
• Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
• Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

• Available humanized models from CIEA, combined with WuXi PDX/CDX models.
• Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

Drug-resistant models

• Engineered cell line derived xenograft models
• Acquired drug-resistant CDX and PDX models
• Intrinsic drug-resistant PDX models
• Resistant models harboring specific oncogenic drivers
• KRAS G12C drug resistant tumor models
• Extensive panel of CDK4/6 inhibitor resistant breast cancer models
• Clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
• Enzalutamide-resistant (LNCAP AR-F877L) mutation KI prostate cancer model
• Osimertinib-resistant cell lines and mouse models